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To Prof. Peter Beighton, ‘Do genetics and see the world.’ … We may not 
yet have seen the world, but we have seen and learnt so much through 
your attention to detail, critical thinking, complex problem solving and 
academic rigour. Your boundless energy and enthusiasm for medical 
genetics and life we will always treasure.
Bardet Biedel syndrome (BBS) (MIM 209900) is a multisystem 
disorder resulting from disruption of cilial function. The most 
consistent clinical features include a progressive rod cone 
retinal dystrophy, obesity, polydactyly and developmental delay/
cognitive impairment.[1] Other frequent associations are urogenital 
malformations, hypogonadism, and both structural and functional 
renal abnormalities.[1-3] Diagnostic criteria have been established 
with these findings listed as primary features.[3] A characteristic facial 
phenotype comprising macrobrachycephaly, with short, narrow 
palpebral fissures, a long, shallow philtrum with thin upper lip 
and downturned corners of the mouth is described.[3,4] The clinical 
spectrum shows overlap with a number of other genetic disorders 
involving abnormalities of ciliogenesis, such as McKusick-Kaufman 
syndrome and Alström syndrome.[5] Additional reports have 
expanded both the ocular and systemic phenotype.[6-9]
BBS is typically an autosomal recessive disorder. Although 
oligogenic inheritance is described, it is a highly heterogeneous 
condition and to date 21 genes (BBS 1-19, NPHP1 and IFT172) 
that account for more than 80% of affected individuals have been 
implicated.[10] Most of the genes code for proteins belonging to 
two functional groups. BBS 1, 2, 4, 5, 7, 8 and 9 are responsible 
for the formation of a complex known as the BBSome, important 
in promoting ciliogenesis. BBS 6, 10 and 12 code for type II 
chaperonins, which contribute to assembly of the BBSome.[11] The 
contribution of these genes to the mutational burden in BBS varies 
between populations. BBS 10 is the major contributor explaining 
20% of cases and, together with BBS 1, 2 and 4 account for ~60% of 
mutations worldwide.[12,13] More than 80% of disease-causing alleles 
are private mutations with, to date, only two mutations, BBS 1 M390R 
and BBS 10 C91LfsX5, accounting for >5% of cases.[12]
The observation that BBS is one of the more frequently encountered 
autosomal recessive disorders in the indigenous black population 
of South Africa (SA) was first made in 1986 by Beighton and 
Botha. [14] In a small collaborative study with the Héon laboratory 
at The Hospital for Sick Children in Toronto in which seven 
SA BBS patients underwent multigene testing, all four black SA 
BBS patients included were found to be homozygous for a 4bp 
deletion in BBS 10 (K243IfsX15)[15] previously identified in four 
Middle Eastern families.[13,16] Different mutations were identified 
in the remaining three coloured patients. Subsequent investigation 
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Background. Bardet Biedl syndrome (BBS) is a multisystem disorder characterised by obesity, polydactyly, intellectual disability and loss 
of vision due to a progressive retinopathy. Although typically a highly heterogeneous autosomal recessive disease, homozygosity for single 
mutation in BBS 10 has been identified in a significant number of affected individuals tested in South Africa (SA). 
Objectives. To delineate the ethnic distribution and clinical phenotype in a cohort of SA BBS patients with the K243IfsX15 mutation in BBS 
10 and discuss the implications for genetic testing of and counselling for this disorder in SA.
Method. This was a descriptive cross-sectional study collating clinical and laboratory data retrospectively in a genetically homogenous 
subgroup of BBS patients from SA.
Results. A total of 76 patients from 74 families were tested. Homozygosity for the K243IfsX15 BBS 10 mutation was found in 50 families 
(67%) and heterozygosity for the same mutation in an additional two affected individuals. With the exception of one patient of mixed 
ancestry, all were black South Africans from different language groups. This is in keeping with the observation that BBS is more common 
in this ethnic group compared with white and coloured patients in SA, first made by Prof. Beighton nearly 3 decades ago. A subset of 
15 patients available for detailed phenotyping confirmed consistency with well-described features of the disorder, with some overlap with 
other ciliopathies. The onset of visual impairment was early in our cohort, before the age of 8 years, cognitive impairment was significant, 
and renal and cardiac abnormalities were infrequently encountered. 
Conclusion. The high frequency of homozygosity for a single mutation in an ethnic subset of the SA population is strongly suggestive 
of a founder effect. This has allowed establishment of a diagnostic test with a high yield in our local population. Better understanding of 
the phenotype will improve earlier recognition of the disorder to allow for appropriate intervention. Testing can confirm but not negate a 
clinical diagnosis, and can permit carrier and prenatal testing in informative families.
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showed that an additional 6/7 patients tested 
carried the same mutation. This, together 
with the finding of a shared haplotype in 
the original cohort, strongly suggested a 
founder mutation.[15] Testing for this specific 
mutation was made diagnostically available 
through the National Health Laboratory 
Service at Groote Schuur Hospital in 2009.
This study was undertaken to delineate 
the detection rate and clinical phenotype of 
a subgroup of BBS patients homozygous for 
the K243IfsX15 mutation.
Methods
A total of 84 South Africans from 74 BBS 
families underwent molecular genetic testing 
between January 2007 and June 2014. In 
eight samples, the indication for testing was 
for carrier status and these were excluded 
from further analysis. Samples were sent 
from many parts of SA, including the 
Western Cape, the Eastern Cape, Gauteng, 
Limpopo, the Free State and KwaZulu-Natal 
provinces.
Results
Of the patient samples tested for the 
K243IfsX15 mutation in BBS 10, homo-
zygosity was found in 50 families (67%) and 
heterozygosity in a further 2 families. In 
the remaining 22 families testing negative 
for this single mutation, 3 coloured patients 
have subsequently had causative mutations in 
other BBS genes identified: 1 with compound 
heterozygosity in BBS 2 and 2 brothers 
heterozygous for novel BBS 10 mutations 
predicted to be disease causing.[6] From the 
limited information available, a number 
of patients testing negative did not have 
more than one or two primary diagnostic 
criteria, suggesting that the diagnosis may be 
uncertain. Ethnicity was not documented for 
all patients, but where available, confirmed 
that all further positive analyses were found 
in patients of indigenous black SA descent, 
with white and coloured patients accounting 
for a significant number of negative analyses.
There was no documented consanguinity 
in any of the families. At the time of analysis, 
there was a wide distribution of ages, from 
2 months to 42 years, with the majority of 
the cohort in the 1st and 2nd decade of life. 
Gender distribution showed a significant 
predominance of males. Further analysis 
of the clinical phenotype was confined to 
15 patients homozygous for the K243IfsX15 
BBS10 mutation who were available for 
comprehensive phenotyping by one or 
more of the authors. Findings were typical 
of those well described in BBS, but of note 
is that all patients were obese, all but one 
had polydactyly involving at least three 
limbs and all male patients had evidence of 
hypogonadism. Visual impairment began 
with poor night vision, but by the age of 8 
years, parents had noticed reduced daytime 
visual acuity interfering with function 
in their affected children. Cognitive 
impairment was considered moderate or 
severe in over half of the group. In some 
of the patients, this had been formally 
assessed by documented Developmental 
Quotient or Intelligence Quotient scores, 
but in others the severity was assigned on 
the basis of functional abilities. In contrast, 
renal and cardiovascular abnormalities 
were infrequent. The spectrum of clinical 
findings in this subcohort is represented 
in Table 1. 
Discussion
BBS is a complex disorder encountered in 
our local population, resulting in significant 
disability for those affected. This study 
provides confirmation that homozygosity 
for the K243IfsX15 mutation in BBS 10 
is a major contributor to the genotype of 
SA BBS patients. Although the majority of 
patients tested were isiXhosa speakers, the 
mutation was also found in BBS patients 
of Sotho and Venda ancestry, suggestive of 
a founder mutation occurring early in the 
migration of bantu language speakers of 
southern Africa. 
The phenotypic expression in this cohort 
of BBS patients reflects the pleiotropic 
effects of cilial dysfunction well described 
in BBS.[2,3] Both intra- and interfamilial 
variability is well recognised, but some 
limited genotype-phenotype correlations 
are emerging.[15,17] The most frequently 
encountered manifestations were polydactyly, 
obesity, visual disturbance, cognitive 
impairment and male hypogonadism, which 
Table 1. The spectrum of clinical findings in a subcohort of BBS patients homozygous 
for the K243IfsX15 mutation in BBS 10 (n=15)* 
Clinical features n (%) Additional comments
Obesity 15 (100)
Typical facies 15 (100) Macrobrachycephaly, deep-set eyes, 
almond-shaped palpebral fissures, large 
ears, low nasal bridge with broad nasal root 
and anteverted nares
Polydactyly 14 (93) Type A postaxial (three or four limbs)
Eyes Pigmentary retinopathy present by the age 
of 7 years.Visual disability 14 (93)
Nystagmus 10 (66)
Cognitive impairment/ 
developmental delay 
Severe 1 (7)
Moderate 8 (53)
Mild 6 (40)
Renal Infantile cystic kidneys/unilateral 
hydronephrosis Structural abnormality 2 (13)
Renal failure 1 (7)
Enuresis 6 (40)
Genital 
Male (n=10) 10 (100) Small/undescended testes, micropenis 
Female (n=5)  1 (20) Vaginal atresia, hydrometacolpos
Hepatic 8 (53) Elevated transaminases
Cardiovascular 
Congenital heart disease / murmur 0 (0)
Hypertension 2 (13)
Endocrine 
Diabetes mellitus 2 (13)
Hypothyroidism 1 (7)
* Age range 2 months - 42 years.
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occurred in >90% of patients. There is no clear explanation for the 
male predominance in patient samples, but it is possible that that 
early detection of hypogenitalism in boys may prompt testing more 
readily. 
Visual disturbance had an early onset in most of our cohort, 
with functional visual disability both at night and in the day 
present by the age of 8 years in the large majority, and all older 
patients examined were legally blind by mid-adolescence. This is 
in keeping with previous reports suggesting that mutations in the 
chaperonin genes associated with BBS may have an earlier onset of 
retinopathy. [15] Developmental delay/cognitive impairment occurred 
in the whole cohort and was more severe than described in more 
heterogeneous cohorts, where intellectual disability occurs in about 
two-thirds of cases and is usually mild in up to 77% of cases.[1,2] All 
but one of our cohort had type A postaxial polydactyly present in at 
least three limbs, which could suggest a high penetrance for digital 
abnormalities with this mutation. 
In contrast with the reported literature, which indicates that 
renal abnormalities and altered renal function occur in >50% of 
individuals with BBS, structural renal abnormalities and disorders 
of renal function as reflected by elevated serum creatinine levels 
were infrequent in our patients.[8,9] An age-related evolution of 
the phenotype is well documented in BBS,[1,6] and the younger age 
distribution of our cohort may have influenced this. Primary enuresis 
was common into late childhood and adolescence in our cohort, 
and likely reflects the recognised urinary concentration deficits 
that occur in BBS.[8] Prospective studies have shown cardiovascular 
abnormalities in up to 52% of BBS patients[9] and an incidence of 
congenital heart disease in BBS of 7 - 19%.[1,7] With the exception of 
two patients with hypertension, clinically significant cardiovascular 
abnormalities were not encountered in our cohort. The clinical 
finding in this subgroup of patients homozygous for the K243IfsX15 
mutation is in keeping with those described in four Omani patients 
with the same genotype.[16]
Genetic testing for highly heterogeneous disorders is not always 
routinely available. A stratified approach of testing in BBS, prioritising 
mutations and genes with greatest frequency, has been suggested,[15] 
although next generation sequencing panels may be a better strategy 
in more heterogeneous populations.[10] In a resource-constrained  SA 
setting with limited access to multigene panels, first-line testing for 
the K243IfsX15 mutation in black South Africans with features of BBS 
is recommended and can be expected to provide a high diagnostic 
yield. Families with a positive genetic diagnosis can then be offered 
the option of prenatal diagnosis and carrier testing of the at-risk 
relatives. Genetic counselling is recommended as the limitations 
and implications of both positive and negative results needs to be 
carefully communicated.
Conclusion
A single BBS 10 mutation (K243IfsX15) accounted for 68% of disease-
causing alleles in this study of  SA BBS patients. Genetic testing 
for this single mutation is simple and cost effective, and allows for 
confirmatory testing in a significant proportion of  SA patients 
in whom a diagnosis of BBS is suspected. It is, however, essential 
that the limitations of testing for a single mutation in a condition 
with such marked genetic heterogeneity be clearly understood and 
communicated when testing is considered and results delivered.[18]
Knowledge of the phenotypic spectrum and age-related penetrance 
of BBS will improve diagnostic accuracy and allow for earlier diagnosis. 
In younger children, a diagnosis of BBS should be considered when 
polydactyly and genital abnormalities are encountered, particularly 
when accompanied by the characteristic facial features, obesity and 
developmental delay. Older children may come to attention when 
presenting for evaluation of obesity, or reduced night vision or poor 
visual acuity. A prompt diagnosis will allow for appropriate care for 
the individual and genetic counselling for the family. 
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